Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products
Genes · 08.04.2024 · 15 (4) · 468
DOI: 10.3390/genes15040468 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 08.04.2024. Verfasst von Yalan Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Hauptthemen laut MEDLINE: Precision Medicine, Biological Products, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
In recent years, the FDA has approved numerous anti-cancer drugs that are mutation-based for clinical use. These drugs have improved the precision of treatment and reduced adverse effects and side effects. Personalized therapy is a prominent and hot topic of current medicine and also represents the future direction of development. With the continuous advancements in gene sequencing and high-throughput screening, research and development strategies for personalized clinical drugs have developed rapidly. This review elaborates the recent personalized treatment strategies, which include artificial intelligence, multi-omics analysis, chemical proteomics, and computation-aided drug design. These technologies rely on the molecular classification of diseases, the global signaling network within organisms, and new models for all targets, which significantly support the development of personalized medicine. Meanwhile, we summarize chemical drugs, such as lorlatinib, osimertinib, and other natural products, that deliver personalized therapeutic effects based on genetic mutations. This review also highlights potential challenges in interpreting genetic mutations and combining drugs, while providing new ideas for the development of personalized medicine and pharmacogenomics in cancer study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- Shanghai R&D Centre for Standardization of Chinese Medicines, Shanghai 202103, China.
ORCID-Profile: Qingzhong Wang
Förderung
- National Natural Science Foundation of China
- Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine
- Shanghai Municipal Health Commission
Zitieren
APA
Zhou, Y., Peng, S., Wang, H., Cai, X., & Wang, Q. (2024). Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products. Genes, 15(4), 468. https://doi.org/10.3390/genes15040468
Vancouver
Zhou Y, Peng S, Wang H, Cai X, Wang Q. Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products. Genes. 2024;15(4):468. doi:10.3390/genes15040468
BibTeX
@article{Zhou2024,
author = {Zhou, Yalan and Peng, Siqi and Wang, Huizhen and Cai, Xinyin and Wang, Qingzhong},
title = {Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products},
journal = {Genes},
year = {2024},
volume = {15},
number = {4},
pages = {468},
doi = {10.3390/genes15040468}
}
EUVIMED